Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Employees - 103,
CEO - Dr. Seth Lederman M.D.,
Sector - Healthcare,
Country - US,
Market Cap - 122.64M
Altman ZScore(max is 10): -9.41, Piotroski Score(max is 10): 3, Working Capital: $35362000, Total Assets: $94989000, Retained Earnings: $-708586000, EBIT: -81394000, Total Liabilities: $20778000, Revenue: $11291000
- Current Price $0.61 - Analyst Target Price $3.25Ticker | TNXP |
Index | - |
Curent Price | 0.61 |
Change | 7.30% |
Market Cap | 122.64M |
Average Volume | 90.89M |
Income | -135.25M |
Sales | 11.29M |
Book Value/Share | 0.48 |
Cash/Share | 0.14 |
Dividend Est | - |
Dividend TTM | - |
Dividend Ex-Date | - |
Employees | 103 |
Moving Avg 20days | 130.08% |
Moving Avg 50days | 205.29% |
Moving Avg 200days | -74.59% |
Shares Outstanding | 186.89M |
Earnings Date | Nov 12 BMO |
Inst. Ownership | 1.51% |
Price/Earnings | - |
Forwad P/E | - |
PE Growth | - |
Price/Sales | 10.86 |
Price/Book | 1.28 |
Price/Cash | 4.34 |
Price/FCF | - |
Quick Ratio | 2.78 |
Current Ratio | 3.33 |
Debt/Equity | 0.12 |
Return on Assets | -115.46% |
Return on Equity | -138.69% |
Return on Investment | -169.47% |
Gross Margin | -18.28% |
Ops Margin | -731.49% |
Profit Margin | -1197.86% |
RSI | 75.07 |
BETA(β) | 1.81 |
From 52week Low | 418.31% |
From 52week High | -97.19% |
EPS | -20.56 |
EPS next Year | -0.62 |
EPS next Qtr | -0.18 |
EPS this Year | 95.88% |
EPS next 5 Year | - |
EPS past 5 Year | 79.31% |
Sales past 5 Year | 0.00% |
EPS Y/Y | -83.05% |
Sales Y/Y | 183.05% |
EPS Q/Q | 87.46% |
Sales Q/Q | -29.26% |
Sales Surprise | -10.41% |
EPS Surprise | 94.07% |
ATR(14) | 0.14 |
Perf Week | 154.30% |
Perf Month | 221.89% |
Perf Quarter | 353.37% |
Perf Year | -94.96% |
Perf YTD | -95.26% |
Target Price | 3.25 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer